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Available online xxxxUnlicensed medicines (ULMs) are those which have not received authorisation from a regulator, as such they do not
have the same reassurances around safety and efficacy as licensed medicines. This study aimed to explore the use of
ULMs from the perspectives of prescribers, pharmacists and patients within the UK National Health Service (NHS)
setting.
Grounded theory was used as a framework, conducting 28 semi-structured qualitative interviews with prescribers,
pharmacists and patients across both primary and secondary care settings. Participants were identified from their
known use of ULMs where possible and a theoretical sampling approach was used to support recruitment of partici-
pants based on the emergent analysis. Analysis followed a constructivist inductive approach, using constant compari-
son to develop initial themes. This was followed by two focus groups, one with patients and one with professionals
where initial analytic findings were presented to participants to further support the development of themes. All inter-
views were audio recorded and transcribed verbatim.
Three sequential schema scripts were identified and used as a framework to explain our findings: ULM prescribing,
pharmaceutical assessment of an ULM and ULM supply. Common and divergent events within these scripts were iden-
tified and analysed in an attempt to explain similarities and differences across primary and secondary care and be-
tween actors. The analysis identified issues around healthcare professional awareness of using ULMs, perceptions of
ULM safety, challenges around what information should be provided to patients and by whom and adds to the debate
around the place of ULMs in treatment pathways. This study highlights the need for a multidisciplinary conversation






An unlicensed medicine (ULM) is a medicine which does not have the
relevant authorisation from the designated healthcare regulator.1 In the
UK, this is the absence of a Marketing Authorisation (MA) from the Medi-
cines andHealthcare Regulatory Agency (MHRA). The EuropeanMedicines
Agency (EMEA) labels ULMs as ‘unauthorisedmedicines’2 and the Food and
Drug Administration (FDA) refers to ULMs as ‘Pharmacy Compounding’.3
In all jurisdictions, the use of such medicines is permitted where existing
authorised medicinal products are not able to meet the specific needs of
the patients.2 This could be due to the lack of a liquid formulation, for ex-
ample for a patient with swallowing difficulties, but also could include
products with an Active Pharmaceutical Ingredient (API) which is not ap-
proved for use in the regulators' country. This commonly incorporatese 121, Sciences Complex, Wharncliffe S
onovan).
ier Inc. This is an open access articproducts with an API which may pre-date the existence of the country's
authorising body, but also products which have been approved in other na-
tions but not adopted in the individual country. Due to the country-specific
nature of ULMs, the actual products which are included in this category
vary. A list of 649 ULMs in use were identified in the NHS at the time of
writing (March 2021)4 Previous research highlights that ULMs are associ-
ated with increased adverse reactions.5 Concerns about the quality of
ULM manufacture6 have led to increased regulation of this process in the
US,7 and this is mirrored in UK.8 This regulation has led to ULMs attracting
higher costs in the UK NHS but in the EU, there have been concerns that
ULMs have offered a cheaper but more risky alternative to licensed
products.9 However, this regulation relates to the quality of the product
only. The products still do not have a MA as an endorsement that ULMs
are safe and effective, so the absence of this can make decision makingtreet, Sunderland, Tyne and Wear SR1 3SD, United Kingdom.
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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on their use centres around clear communication with patients about the
risks and benefits of using such medicines.
The lack of a MA for ULMs also results in a reluctance for their recom-
mended use at a national level in the UK, by bodies such as the National In-
stitute for Health and Clinical Excellence (NICE). General guidance on their
use and best practice recommendations have been produced by the General
Medical Council (GMC)10 and Royal Pharmaceutical Society (RPS) in the
UK.11 Work conducted by us has analysed the content and quality of guid-
ance documentation available on ULM use within individual healthcare or-
ganisations in the NHS.12 Substantial inconsistencies between guidelines
were identified resulting in a lack of clarity on how decisions about ULMs
are made. Therefore, we identified that exploring this qualitatively would
be beneficial to understanding how ULMs are used within the NHS.
The concept of ‘schema’was first posited by the child development psy-
chologist Jean Piaget who employed the concept to explain the develop-
ment of learning in children.13 A schema can be defined as a set of linked
mental representations of the world, which are used to both understand
the world and to respond to situations in it. Schema (or schemata) are
stored and applied when needed. New information and experiences are
compared to existing schema which can be modified.14 The process of re-
ceiving new information and incorporating it into schemas continues
until equilibrium is reached i.e. a state of cognitive (mental) balance. This
equilibrium is maintained until additional information is received. Thus,
schemas are shaped by learning and new experiences. Schemas have previ-
ously been used as a framework to describe prescribing decisionmaking by
medics15 and patients' perspectives of medicines.16
It was suggested by Schank and Abelson17 that schemas can also be fur-
ther subdivided into scripts, goals and plans. Scripts aremade up of individ-
ual events or actions. Scripts can also be personalised to the individual, who
may change the events in their own script whilst still acknowledging a com-
mon script that most people will understand. Scripts exist from the perspec-
tive of one particular ‘actor’ (in this paper we will call them the script
‘owner’) but may involve multiple actors. In this paper, the schema repre-
sent actors from both primary and secondary care and include prescribers
(both medical and non-medical), pharmacists and patients. Each script is
different depending on the different actors' point of view but a ‘whole
view’ of a script can be created by considering a combination of these
scripts together. In this paper, script schema is used as a framework to un-
derstand the scripts and events associated with ULM use from the perspec-
tives of different actors. It is important to note that the aim of this approach
was not to determine whether ULMs should or should not be used, but to
explore how they are used within the UK NHS.
1.1. Aim
To create amodelwhich describes the use of ULMs from the perspective




A qualitative method was employed to allow for an open exploration of
ULM use in current practice. A constructivist grounded theory approach18
was used. This approach places emphasis on the phenomena which are
being studied and considers that both the data and the analysis of that
data are created from the experiences shared amongst the researchers and
participants and the relationships that exist within and between these. Em-
phasis is placed upon how participants construct meanings and perform ac-
tions in certain situations. It goes beyond describing how participants view
their situation by theorising both the interpretive work that participants do
and recognising that the researchers' explanation is itself an interpretation.
Constructivist grounded theory moves beyond the purely descriptive by
combining themes from the data, the things participants do and say, and2
using them to construct higher order theories tomake sense of actors'mean-
ings and behaviours. Our higher order theory was to use schema scripts.
2.2. Sampling
The sampling frame for the study focused on the actors who made deci-
sions about the use of ULMs. This included the prescribers who initiate
ULMs, pharmacists who procure the ULMs and patients who take (or not)
the medicine. Purposive sampling was initially used to select one partici-
pant from each of these actor groups separately for both care settings. The-
oretical sampling was used following initial analysis of the data to identify
participants who could corroborate or provide divergent views in relation
to the emergent themes. This was done across both work strands through
regular discussions between GD and LP.
The inclusion of off-label medicines was not originally planned. How-
ever, we found that participants in both the patient and healthcare profes-
sional (HCP) groups frequently confused off-label prescribing with ULMs.
Therefore, it was felt that the data captured both elements. For ease, we
will refer to ULMs throughout this paper.
2.3. Data collection
Two methods of data collection were employed. First, face-to-face semi
structured interviews were conducted with participants between June and
November in 2015. Topic guideswere developed based on the aims and ob-
jectives of the study and previous work on an ULM guideline analysis.47
Three versions of the topic guide were developed, one for each participant
group (prescribers, pharmacists and patients). The guides used were com-
mon to both primary and secondary care but evolved based on the emerg-
ing analysis for each strand as per the principles of a constant comparison
approach.19 Interviews were conducted by GD and LP. Copies of these
topic guides are available in the supplementary materials. As we expected
the topic guides to change as data collection and analysis progressed, we
did not pilot these prior to use. Interviews took place in a location and
space agreed upon with the participant. This was most often within consul-
tation rooms in general practices and office space in secondary care, but
also patients' homes. No additional persons were present beyond the partic-
ipant and the researchers in any of the interviews. Each participant was
only interviewed once.
After initial data analysis using the grounded theory approach, findings
were presented to participants in two focus groups, one for patients and one
for HCP participants. The focus groups took place in February 2016 and
were led by GD with support from LP. A topic guide for both focus groups
was developed based on an interim analysis, to share the themes which
had been identified. Sense checking theories from the analysis with actors
is a common technique of the constructivist grounded theory approach, in
order to confirm researchers' understandings and explanations.20
Interviews and focus groups were audio recorded and transcribed ver-
batim prior to data analysis. Transcripts were not returned to participants
prior to analysis due to project time constraints. Rather, focus groups
were used as an opportunity for participants to comment on the emergent
findings. Field notes were also made by both researchers following inter-
views to capture any additional data relating to the study.
2.4. Data analysis
Transcripts from both the interviews and focus groups were used as the
primary data for analysis. Initial inductive coding was undertaken by GD
for the primary care strand, and LP for the secondary care strand. Constant
comparison between the data and codes from both strands, combined with
regular discussions betweenGD and LP allowed for analytic refinement and
agreement of joint and divergent codes to identify genuine differences be-
tween the strands. This discussion also facilitated agreement that data sat-
uration had been reached at the end of the study. Final consolidation of
codes across both strands was led by GD with input from LP. Findings
based on the identified themes from the secondary data analysis were
Table 1
Summary of demographic characteristics for healthcare professional interview
participants.
Demographic information Interview participants (N)
Healthcare professional years of
experience
Prescribers
Newly qualified (up to 5 years) 2
Mid-career (6–20 years) 3
Late career (21+ years) 6
Pharmacists
Newly qualified (up to 5 years) 4
Mid-career (6–20 years) 3
Late career (21+ years) 3
Healthcare professional
specialties























Summary of demographic information for patient interview participants.
Demographic information Interview participants
Age (Years)
Patient age (n = 6a)
Mean 48
Range 21–67















a Age information unavailable for one participant.
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psychological theories. This led to the use of the script schema to support
the explanation of the results. NVivo 1121 was used to facilitate the analysis
process.
2.5. Participant recruitment
For interviews, HCPs in secondary care were recruited via email in one
NHS hospital trust in [redacted]. Prescribers issuing ULMs were identified
prior to sampling. All pharmacistsworkingwithin the trust were considered
within the sampling frame. Patient participants were identified during out-
patient clinics where ULMs were prescribedwith the permission of the pre-
scriber for that clinic.
Primary care participants were recruited across the region of [redacted]
for interview. It was assumed that all HCPs would have had some experi-
ence with ULM's given the high prevalence of prescriptions within this set-
ting. Recruitment of HCPs was via emails through professional networks of
GD. Patients were identified from general practice records as prescribed an
ULM and recruited via a letter. All participants who had participated in an
interview were invited to attend the relevant focus group.
The researchers did not have any prior relationship with patient partic-
ipants, but often had a relationship with HCP's recruited through profes-
sional networks. Participants received an invitation letter from the
research team and a participant information sheet for both the interviews
and focus groups. In these materials all participants were informed of the
study aim, with patient participants being informed that they had been
identified as a suitable participant as theywere prescribed anULM. Second-
ary care prescribers were also informed that they had prescribed an ULM. It
was made clear in participant information sheets for pharmacists and pre-
scribers that we were not seeking to judge the use of ULMs, but to explore
how they are used and therefore avoid participants feeling that they were
under any form of scrutiny. Healthcare professionals were not provided
with any incentive to participant in the research, but patients were pro-
vided with a £20 voucher as a ‘thank you’ for their time both for the inter-
view and attendance at the focus group. Consent formswere provided to all
participants to return to the research team prior to arranging data collec-
tion. This was done for both the interview and focus group elements of
data collection. The number of invitations to potential participants was
not able to be collected. For patients, we did not have these figures as we
did not directly contact patient participants as they were approached in-
stead by their prescriber or GP practice. For professionals, we did not
keep a tally of invitations through professional networks as we often used
groups emails. Thus, non-participation for primary and secondary care
could not be determined.
2.6. About the researchers
GD and LP are both female pharmacists, working in joint roles within
academia and the NHS. GD within an NHS commissioning organisation
and LP in an NHS hospital setting. Both undertook training in qualitative
data collection and analysis prior to the study. GD also had previous expe-
rience of qualitative research methods.
2.7. Ethical approvals
The study was given a favourable opinion by Yorkshire& The Humber -
Leeds West Research Ethics Committee (Reference 17/YH/0191) and ap-
proved by the University of [redacted].
3. Results
Twenty-eight participants were recruited to the study. Seven were pa-
tients and 21 were HCPs. HCPs included community pharmacists (n = 3),
general practice pharmacists (n = 2), General Practitioners (GPs) (n =
5), secondary care prescribers (n = 6) and hospital pharmacists (n = 5).
The sample characteristics for healthcare professionals can be found in3
Table 1 and for patients in Table 2. The average length of an interview
was 44 min, with interview times ranging from 18 min to 74 min.
Additionally, four people (n=1 community pharmacist, n=2hospital
pharmacists, n= 1 secondary care prescriber) attended the focus group for
HCP participants lasting 74 min. Three individuals attended the focus
group with patients which lasted 33 min.
Analysis identified schema scripts describing three sequential stages as-
sociatedwith ULMuse. These were: prescribing an ULM (Stage 1), pharma-
ceutical assessment of an ULM (Stage 2) and supply of an ULM (Stage 3).
These sequential scripts were identified through data analysis from all par-
ticipants from both the interviews and focus groups. Script compilation
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events making up each of these scripts.
3.1. Prescribing of ULMs Script
The first stage of ULM use is described in the prescribing of ULMs script
as seen in Fig. 1. The owners of this script are prescribers. Outside actors
have also provided data on this script from their perspectives. Some events
are only present in either primary or secondary care and these are noted
using protruding arrows. Events within the script are also classified as ei-
ther: agreed amongst all actors, inconsistently described amongst actors
or expected by outside actors but not the script owners. The events have
been organised in an order similar to that described by our participants,
however this is not fixed and the timing of events could be variable.
3.1.1. Receive prescribing request from secondary care
Receiving a request from secondary care to prescribe an ULM was a
unique event to participants from primary care as part of the prescribing
of ULMs script. There were mixed feelings about the transfer of care for
ULMs, often due to the unfamiliarity of primary care prescribers with
these medicines.
“I think the shift from hospital to community is just fraught with possible mis-
takes. Because you're asking people who don't use that medicine to prescribe
that medicine when they may not be au fait with that medicine.” General
Practitioner 3, Interview.
3.1.2. Apply for ULM to be on local formulary
In secondary care, participants described applications for ULMs to ap-
pear on the local formulary as a pre-requisite for prescribing an ULM.
“I had to liaise with our pharmacy to say this was a specific preparation that I
was going to want to continue giving. For these reasons, I had to justify it. I
think I went to our pharmacy group, or prescribing group within the Trust,
to check that people thought it was reasonable.” Secondary Care Prescriber
6, Interview.
3.1.3. Recognition of the ULM
Recognising an ULMwas an event that was identified by all participants
as important to the subsequent use of ULMs. However, thereweremixed re-
ports in the data about how often this event formed part of prescribers'
scripts. GPs, less experienced doctors and nurse prescribers reported thatFig. 1. Diagram representing schema script events for S
4
they were not always sure when they were prescribing an ULM. This lack
of awareness was often attributed to prescribing systems not necessarily
alerting them to the medicines' status.
“So if it comes up and you're maybe a newly qualified doctor, or a GP regis-
trar, you'd just think, ‘well, if it comes up when I type it in, it must be alright to
use, because it's on the system’, without realising what it's licensed in or
not…” General Practitioner 1, Interview.
3.1.4. Establish the cost of the ULM
In primary care, an event to establish the cost of the ULM did not appear
in data collected from secondary care. Primary care prescribers seemed to
have a heightened awareness of ULMs being high cost and this was some-
times found to be a source of conflict when attempting to transfer care for
patients receiving ULMs. Patients were also aware of costs in relation to
the prescribing of ULMs script.
“I know one of the medications that [my daughter] was on, the Acetazol-
amide, which just this year we couldn't get the tablet form sowe ended up hav-
ing to get the liquid form, but that was very expensive and obviously the
doctor was a bit reluctant to give her it.” Primary Care Patient 1, Interview.
3.1.5. Considering all available treatments
All prescribers described the consideration of all available treatments to
meet patient need. It was consistently agreed that a licensed medicine
should always be used in preference to an ULM. However, once a licensed
medicine was unable to meet the needs of the patient, the choices which
came next in terms of preference were unclear. There was also evidence
of some ULMs being used as part of established practice, and this led to
less emphasis on considering a large range of alternative treatment options.
The patients' over-riding concern was that they were not comfortable being
used as a “guinea pig”, and therefore felt that the prescriber should have
some experience which supported the selection of an ULM.
“You've reached the end of what is licensed or perhaps what is you know the
clinical first, second, third line agent and you're left with little or no choice re-
ally.” Secondary Care Prescriber 2, Interview.
3.1.6. Seek further information about the use of the ULM
Ensuring that prescribers had all the relevant information to safely pre-
scribe ULMs was common to primary and secondary care scripts. However,tage 1: Prescribing an unlicensed medicine (ULM).
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mary care where information available might be limited. Primary care pre-
scribers often relied on information provided by secondary care clinicians
who were often the source of the prescription request. In secondary care,
experienced clinicians described using research literature or experience of
colleagues as sources of further information.
“If it's a special then I'll either have to look it up in the BNF and often the in-
structions get very vague. So often when it's unlicensed unlicensed or it's just
really special, they'll often have very, very vague instructions. Or no instruc-
tions and they'll simply list it. In which case then I know I need to find out
more.” General Practitioner 3, Interview.
3.1.7. Evaluate the safety of the use of the unlicensed medicine
Most prescribers acknowledged that the safety profile for ULMs was dif-
ferent to that of a licensed medicine and evaluating the safety for the use of
an ULMwas a distinct event. However, prescribers generally perceived that
ULMs were safe. This opinion seemed to be based on a lack of reports from
patients that any adverse events had occurred. Some prescribers however,
reflected that this perception might change if they did have a patient who
experienced harm from an ULM. Safety was a primary concern of the pa-
tient participants, although all trusted the judgement of their prescribers.
“Well, at first, it was only when I read all this I think, I just sort of thought ‘oh,
are they testing it?’ That was my first thought. Is it still sort of not one hundred
percent safe? Has it been tested? That was all. But I wasn't unduly bothered or
anything. I'm not that type of person you know.” Primary Care Patient 3, In-
terview.
3.1.8. Consider increased responsibility for using a ULM
When considering the implications of using an ULM, most pharmacists
highlighted the increased responsibility that prescribers attracted in the ab-
sence of aMA being in place. They expected that this was considered as part
of the prescribing anULM script. However, prescribers themselves often did
not differentiate their liability for prescribing ULMs and that of licensed
medicines. Therefore, this was an eventwhichwas expected by pharmacists
but not included in prescribers' script.
“I think if something is used a lot and is within recognised medical practice
then I don't think I worry about the fact that it's unlicensed any more than
something being licensed, because I don't think it really matters to be honest.”
General Practitioner 5, Interview.
3.1.9. Inform the patient that the medicine selected is unlicensed
Most prescribers intended to inform their patients that their medicine
was unlicensed as part of a shared decision-making process. Patients and
pharmacists also expected that this should be an event in the prescribing
of ULMs script. However, prescribers' lack of awareness of whichmedicines
were unlicensed was a barrier to including this event in their scripts. Some
prescribers were reluctant to inform patients, including one who actively
chose not to inform their patients.
“…if we have some with side effects then I would say this and this side effect.
That's important, the fact that it's unlicensed or licensed is not important.”
Secondary Care Prescriber 6, Interview.
For patient participants, those recruited from secondary care reported
being informed that their medicine was unlicensed as part of the prescrib-
ing script, however none recruited from primary care had been informed al-
though all had their ULM initiated by a hospital prescriber. All patients
however, felt that this should be an event as part of the prescribing script.
“I think I would have liked to have known it was unlicensed. I didn't know un-
til you toldme. I still don't think I would have been worried about it though…”
Primary Care Patient 4, Interview.5
3.1.10. Provide information about the unlicensed medicine
Within the data, prescribers in both primary and secondary care re-
ported endeavouring to provide patients with information about their med-
icines. The content of this information generally included the indication of
the drug, potential side effects, length of treatment, expected treatment out-
comes and how to use the medicine. For prescribers, there was generally no
perception of difference between this event as part of prescribing an ULM
script and their equivalent script for licensed medicines. Many prescribers
felt that they would benefit from providing written information about
what an ULM was, however, could not identify a source for this.
“It wasmore just what will happenwhen you use it because it's obviously quite
an unusual use, and the side effects of it. …So that was the counselling that
they gave.” Primary Care Patient 5, Interview.
3.1.11. Gain agreement with patient on use of the unlicensed medicine
Where prescribers were happy to inform patients that their medicine
was unlicensed, this was linked to another event where they would gain
agreement for using an ULM with the patient. Some patients also reported
positive experiences of shared decision making with their prescribers.
“I do believe the consultant actually said to me ‘go home, have a look at it,
next appointment we'll see.’ So I went away, did a bit of research and I
thought the uses of, in a controlled situation, I thought ‘well, the least I can
do is give it a try’” Secondary Care Patient 2, Interview.
3.2. Pharmaceutical assessment of ULMs script
The second stage of using an ULM described by our participants is rep-
resented by our pharmaceutical assessment of an ULM script as shown in
Fig. 2. The owners of this script are pharmacists working in either commu-
nity pharmacy, general practice or secondary care. Whilst this script was a
precursor to the supply of ULMs script for hospital and community pharma-
cists, GP pharmacists used this script as part of medication reviews.
3.2.1. Recognition of the ULM
Although recognition of an ULM event was present in both primary and
secondary care, community pharmacists reported being able to quickly rec-
ognise an ULM. Hospital pharmacists based on wards cited their removal
from the dispensing process to conduct clinical work on wards meant that
they were less aware of which medicines were unlicensed.
“Generally in the computer system, if you do a stock enquiry if it's unlicensed
it would just have a code UNL on the stock code, so you would know it that
way. But when you look at it on the paper order, you don't.” Hospital Phar-
macist 2, Interview.
3.2.2. Speak to the patient to gather information about the use of the ULM
Speaking to the patient was an important event for community pharma-
cists in order to gather information about ULM use as part of their pharma-
ceutical assessment of the ULM script. Patients provided information about
their use of the medicine and allowed an assessment of what information
the patient knew. This could then be used to tailor the provision of informa-
tion event as part of the ULM supply script.
“I would maybe just go out and advise them. Have they had this before? Do
they understand what it's being used for?” Community Pharmacist 2, Inter-
view.
3.2.3. Check formulary status of the ULM
In secondary care, checking the status of an ULM on the local formulary
was a unique event for hospital pharmacists. This enabled assessment of
likely availability of the ULM and provided information about how their
hospital categorised the risk of the ULM.
Fig. 2. Diagram representing schema script events for Stage 2: Pharmaceutical assessment of an unlicensed medicine (ULM).
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The simple things like is the label in English. Have we got the certificates of
analysis or certificates of conformance if it's made in the EU. We also look
at the packaging, for the directions if they want supplementary information.
So those are the types of things that we look at.”Hospital Pharmacist 1, Inter-
view.
3.2.4. Check if an ULM is required to meet clinical need
An event to check if an ULM was required to meet clinical need was
common to both primary and secondary care, however this event appeared
less consistently amongst community pharmacists. In common with pre-
scribers, hospital pharmacists and general practice pharmacists described
a wide range of potential alternatives to using an ULM with a preference
for using a licensed medicine first. Amongst pharmacist participants how-
ever, there was more consistency for considering off-label uses of licensed
medicines as the next best alternative to an ULM. One GP pharmacist
who also had experience working as a community pharmacist highlighted
the challenges of performing this event in the community pharmacy setting.
In particular, time available and access to specialist resources.
“I can honestly say I don't know any community pharmacists that would pro-
actively look at someone who's taking a special and think ‘oh, should we try
and change this?’” GP Pharmacist 1, Interview.
3.2.5. Seek further information about the use of the ULM
Pharmacists across primary and secondary care reported seeking further
information about ULMs as part of the pharmaceutical assessment script.
Pharmacists generally reported accessing a wider range of resources to sup-
port their decision making compared to prescribers in the equivalent event
as part of the prescribing an ULM script.
“…probably first I would try the BNF. If it's something like a monoclonal an-
tibody or something a bit more exotic that's not going to be in the BNF, then I
would either have a look in Martindale or probably look up the [Summary of
Product Characteristics]” Hospital Pharmacist 5, Interview.
3.2.6. Evaluate the safety of the ULM
For all pharmacist participants, evaluating the safety of an ULM was a
key event with the pharmaceutical assessment of an ULM script. However,
in addition to the acknowledged lack of safety information reported by pre-
scribers, pharmacists also considered risks in relation to the formulation of6
the ULMs. Pharmacists often contextualised ULMs as ‘adaptations’ of li-
censed medicines.
“Most of the specials that we deal with are just a variation on something that
is licensed and they just realise it's done slightly differently.” Community
Pharmacist 1.
3.2.7. Inform the prescriber that the medicine is unlicensed
There were mixed reports amongst pharmacists about whether rou-
tinely informing the prescriber that the medicine was unlicensed was an
event as part of the pharmaceutical assessment script. Most described mak-
ing a judgement about whether the prescriber was likely or not to know
that the medicine was unlicensed based on the frequency with which the
ULMwas used and their knowledge of the prescriber themselves. However,
most prescribers felt that this was something that should happen.
“I think it's important that the pharmacist[s] let us know. They say, ‘wait a
minute this is unlicensed’.” General Practitioner 2, Interview.
3.2.8. Seek clarification of changes to the ULM prescription if needed
Where issues arose as a result of the pharmaceutical assessment script,
pharmacists described an event where they would either seek clarification
that the prescriber intended to use an ULM or suggest changes to the ULM
prescription. Prescribers also described these interactions. Some pharma-
cists felt that prescribers saw these conversations as an inconvenience,
but there was also evidence that these were valued.
“They double check things and they ring you up if they're unsure, or if you've
made an error they'll check it, and they'll come back to you with that. So there's
always that safety net as well, and even if they pick up on something, then you
think ‘well actually, I'll not do that again.” Secondary Care Prescriber 4,
Interview.
3.3. Supply of an ULM script
Stage 3; supplying an ULM (see Fig. 3). With script owners being com-
munity and hospital pharmacists.
3.3.1. Select supplier for the ULM
Selecting a supplier for the ULM was an event shared by primary and
secondary care, but with discrepancies. Community pharmacists working
for national pharmacy multiples for example, had a set ULM supplier se-
lected for them by a head office organisation. However, community phar-
macists working for independent and smaller companies reported having
Fig. 3. Diagram representing schema script events for Stage 3: Supply of an unlicensed medicine (ULM) to the patient.
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flexibility could be used to meet either commercial or patient interests.
When asked about what made a supplier favourable, community pharma-
cists placed an emphasis on customer service. In secondary care however,
hospital pharmacists relied on centralised processes for supplier selection.
One hospital pharmacist described systems in place to evaluate suppliers
on a case-by-case basis.
“When the [ULM provider] representative calls I will go through, what is it
that you do, what's your background, how big is your company? How long has
it been trading? What sort of preparations do you make and can you give me
an idea of your facilities that you've got? To try and build up a picture and it
may be that sometimes we want to go out and visit them.” Hospital Pharmacist
1, Interview.
3.3.2. Establish the cost of the ULM
Establishing the cost of the ULM was mentioned as an event by most
community pharmacists and reflects the event in the prescribing of ULMs
script in primary care. As predicted by our GP pharmacists, community
pharmacists did not report contacting prescribers to seek an alternative
product based on higher costs. Establishing the cost of the ULMwas not de-
scribed consistently as an event amongst hospital pharmacists. Data from
participants suggested that this would only be considered in secondary
care if there were multiple ULMs required by a patient.
“…when I'm on the ward where they're deciding to switch an old lady who
can't swallow or whatever onto a load of liquids or something like that, then I
do think about cost a little bit.” Hospital Pharmacist 1, Focus Group.
3.3.3. Inform the patient that the medicine selected is unlicensed
Provision of medication counselling by pharmacists is a common ele-
ment of medicines supply. In the case of an ULMs however, there was
much debate amongst participants about whether informing the patient
that their medicine was unlicensed was part of the ULM supply script.
There were mixed opinions from pharmacists, with many reporting uneas-
iness about having this conversation with patients.
“I would have expected the doctor to be explaining this, especially as it's quite
unusual for them to be prescribing it. I would imagine they would have got a much
more thorough explanation from the GP.” Community Pharmacist 3, Interview.
Prescribers also expressed discomfort about pharmacists informing pa-
tients that the medicine is unlicensed as part of the medication supply
script.
“…would the pharmacist necessarily tell them? Because the pharmacist
wouldn't know what they're getting it for. They don't know the indication, they
just know what the drug is being given.” General Practitioner 1, Interview.7
Patients also expressed a preference for this step to be included in the
prescribing of ULMs script rather than the medication supply script.
“… I would expect the person prescribing to explain to me what that it is. I
don't think I would expect it from the pharmacy….” Primary Care Patient 2,
Interview.
3.3.4. Provide verbal information about the ULM
Pharmacists in community pharmacy agreed that providing verbal in-
formation to patients was part of their ULM supply script. However, the
content of this information differed from that in the prescribing script. Pro-
viding information in the medication supply script typically included: lag
time for the ULM to be available for collection, availability of information
about the ULM, manufacturing of ULMs, potential for reduced shelf-life,
special storage conditions, and the liability for adverse drug reactions rest-
ing with the prescriber rather than the manufacturer. Hospital pharmacists
however, did not always describe providing verbal information about
ULMs to patients as part of their ULM supply script.
“If there's a short self-life on the products, that kind of thing, different storage
things. I make a big deal of making sure the patient knows about them because
you don't want the products wasted.” Community Pharmacist 3, Interview.
3.3.5. Provide written information about the ULM
There was an expectation from prescribers that pharmacists would pro-
vide written information about ULMs as part of the ULM supply script.
However, pharmacists described difficulties in fulfilling this event as part
of the script. This included difficulties where imported ULMs came with in-
formation in a foreign language or where an ULM had been manufactured
and a leaflet was not supplied. Patients also reported not receiving written
information about their ULM.
“… [The ULM is] Canadian and it's in French, and English, but there is no
ingredients on it or a leaflet with anything, it's just a bottle.” Patient Participant,
Focus Group.
3.3.6. Complete paperwork
Completing paperwork was an event in the ULM supply script for phar-
macists in both primary and secondary care, but eachwith a different focus.
The purpose of the paperwork in secondary care was to quantify risk asso-
ciated with use of ULMs and highlight this to the prescribers. However,
some saw this as more of a bureaucratic process. The paperwork in primary
care seemed to relate primarily to reimbursement.
“My personal thing is not so much is it clinically appropriate, it's is all the pa-
perwork correct and available and filled in.” Hospital Pharmacist 5, Interview.
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This study is the first study that we know of to investigate the use of
ULMs within the NHS using the perspectives of prescribers, pharmacists
and patients across both primary and secondary care settings. This ap-
proach has allowed us to compile a comprehensive system overview
using data which can be categorised according to schema scripts. The
scripts have provided useful insights into the events which make up the
use of ULMs. This includes how the different actors interact with each
other and their perceptions of theirs and others' roles in the use of ULMs.
To develop ULM schema scripts, pharmacists and prescribers need to be
taught what an ULM is. Only pharmacists in our datawere generally able to
correctly define an ULM. This may be due to a greater emphasis on drug
manufacturing and legislation as part of their core training, however our
less experienced pharmacists were still less confident about these defini-
tions and this is reflected in other work.22 Another paper has also
highlighted the potential for confusion surrounding the use of unlicensed
and off-label use of medicines.1 In the UK, the GMChas further complicated
the issue by combining both off-label and ULM within the same guideline1
despite the guidance note from the MHRA making clear differentiations in
risk between these two categories.23 In a previous analysis of 52 guidance
documents for ULMs, 23 different versions of terminology were used to de-
scribe these medicines47 so it is unsurprising that HCPs find these defini-
tions difficult to understand. Non-medical prescriber participants in our
study noted that they were initially not permitted to prescribe ULMs, and
therefore teaching about these had been omitted from their original train-
ing with no updates or additional training offered subsequently. Consistent
definitions are needed to better support comprehension of terminology as-
sociated with ULMs across healthcare professionals.
Knowing that a medicine is a ULM is also important. Hospital pharma-
cists' awareness of using anULMwas limited compared to community phar-
macists, who had additional supply script events in their schema. The
prescribers in our sample working in paediatrics and ophthalmology de-
scribed routine use of ULMs and were more aware of when they were
being used. To date, most research around ULMs has centred on their use
in paediatrics2,24,33,25–32 and the EMEA has written specific guidance
about safety considerations in this patient group34 and so they are likely
more familiar with ULMs, and also that many more medicines are used
off-label in this patient group. Clinical speciality has been suggested to in-
fluence the formation of schemas in relation to prescribing by others.15
Once it has been established that an ULM is being used, it is then impor-
tant to consider how this potentially changes the use of the medicine. In
contrast to our pharmacists who clearly articulated the lack of MA as put-
ting both the prescriber and the supplying pharmacist in a greater position
of responsibility, prescribers did not differentiate ULMs and licensed medi-
cines in their clinical decision-making process. The GMC have also implied
that prescribing unlicensed and off-label medicines does not put pre-
scribers' registration at any greater risk,1 and therefore there is a clear dis-
crepancy in message about the risk that prescribers take on when using
these medicines.
Consideration of safety is clearly an important part of this risk assess-
ment. This was present in all three of our scripts and from all perspectives.
In the UK, ULM manufacturers report adverse reactions to the MHRA.35
Pharmacists and prescribers also report ADRs via the Yellow Card
Scheme.11,23,36 However, data for the MHRA Yellow Card Scheme is only
published by API without associated formulation, so ULMs and licensed
medicines cannot be differentiated in the data. A lack of evidence for
ULM safety has been highlighted by other research,37 where patient regis-
tries have been suggested as a way of capturing adverse events to better
support understanding of their safety. Assessment of risk is also included
in guidance published by the RPS.11,36 In particular, the RPS highlight the
lack of information clinicians have available to make informed decisions
about prescribing ULMs. Potential pharmaceutical issues with ULMs have
also been highlighted by others.22 However, risk perception by individuals
is influenced by an availability bias; most participants in this study could
not describe an significant adverse consequence from using an ULM and8
this can create biases in the formation of schema.38 This combined with
the absence of robust data could lead to the conclusion that ULMs are
safe to use.
Risk of ULMs also needs to be weighed against potential benefit. The
pharmaceutical assessment of ULMs script described reflects the principles
of pharmaceutical care first described by Hepler and Strand,39 where the
objective is to ensure the best outcomes for patients from drug therapy.
There was much debate about the place of ULMs in treatment pathways.
This assessment was hampered by the information deficit for ULMs. Pa-
tients were grateful for the opportunity to try something that they found
to be effective, and specialist prescribers were very comfortable using
ULMs as part of routine practice. It has previously been found that guide-
lines attempting to place ULMs within a treatment pathway did not
agree,47 making the place of ULMs still unclear. Speciality specific guide-
lines have previously been identified on the use of ULMs47 including in
ophthalmology40 and dermatology41 and NICE have also started producing
evidence summaries for ULMs.42 More guidelines for use of ULMs could
support healthcare professions to make better judgements on the place of
ULMs within treatment pathways and support the development of formu-
laries of ULMs. Formularies have been recommended by others as another
way to oversee the use of ULMs11,43 andwas highlighted as valuable by par-
ticipants in our schema scripts.
Use of ULMs is also based on a cost-effectiveness decision. Awareness of
the cost implications of using ULMs was present only amongst those actors
present in the primary care setting. Higgins and Tully15 also found that cost
is of little consideration to prescribers working in secondary care when
making prescribing decisions. Pharmacists working in general practice re-
ported costs in their pharmaceutical assessment script and this is likely
due to prescribing budget management being part of their role.44 We
have previously highlighted the increased cost associated with ULMs45
however there remains some debate about what impact this should have
on their use.
On a more practical level, ULMs also pose some challenges that our
work also highlights, the provision of patient information. Prescribers in
this study often assumed that written information would be provided by
pharmacists as part of the ULM supply script and had little awareness of is-
sues pharmacists faced sourcing information. Patients provided evidence
that access to high quality written information about their ULMs was
poor and this reflects other studies which have also found lack of informa-
tion associated with ULMs.25 A national repository of such information
would support the more consistent availability of patient facing informa-
tion across the NHS.
Our ‘whole system’ approach also allowed us to example how the differ-
ent care settings worked together to support the use of ULMs. Collaboration
across HCP boundaries was present in the data both from pharmacist and
prescriber perspectives, including the transfer of ULMs across care bound-
aries. This importance of good transfer of ULMs is highlighted in guidance
for ULMs by the RPS.11,36 All our participants highlighted issues around the
transfer of care for ULMs and this has been reflected in work by others.22
Primary care prescribers described having a lack of knowledge about
ULMs and costs of ULMs were also cited as barriers in prescribing transfer.
These issues have also been found in otherwork done on the transfer of pae-
diatric patients from secondary to primary care.25,28
Central in the data howeverwas the debate aroundwhowas best placed
to inform the patient that the medicine they were using was unlicensed.
Guidance from the RPS seems to indicate that the responsibility for this
should rest with the prescriber,11 therefore in our framework this should
be contained within the prescribing script and this position was supported
by our participants and has been reflected in work by others.32,33 However,
given the challenges that prescribers face around awareness of when they
are using an ULM, applying this in practice is likely to be difficult. Whilst
others have explored pharmacists' perceptions about informing patients
about the status of ULM22 or off-label use of medicines,29,32,33 we are the
first to include this debate from several actors' perspective. We feel that
this is something that will need ongoing discussions between prescribers,
pharmacists and patients.
G. Donovan et al. Exploratory Research in Clinical and Social Pharmacy 2 (2021) 1000174.1. Strengths and limitations
Whilst others have used schemas to illustrate the process of
prescribing,15 we are the first to use this to describe the use of ULMs. We
also expand the use of script schema to processes carried out by pharmacists
for pharmaceutical assessment andmedication supply. This study also used
qualitative approaches to capture the delivery of pharmaceutical care and
this has previously been highlighted as lacking in pharmacy practice
research.46 This study adds to the data for the difficulties HCPs face in
conceptualising ULMs and how they are used in practice. Many of the
schema script events we describe are also reflected by others15,22,29 and
we feel this adds to their likely transferability.
All qualitative approaches are limited by the self-selection of their par-
ticipants who choose to be involved in the research. We have attempted
to combat this by using a theoretical sampling strategy, where we recruited
new participants based on emergent themes. Therefore, feel we have a di-
verse sample upon which we have based our analysis. No new themes
emerged towards the end of our data collection, and therefore we feel
that our analysis is likely transferrable to other settings within the UK.
We have not found similar studies internationally, so we do not know if
these scripts would be transferable internationally. We did only sample
from one secondary care institution which may limit some of our findings,
specifically concerning governance structures and roles, however, these are
still likely to be common amongst most secondary care settings.
5. Conclusion
This work outlines three schema scripts for prescribing, pharmaceutical
assessment and ULM supply which sheds light on how ULMs are used
within the UK NHS. These scripts highlight the difficulties associated with
using ULMs and the assumptions that actors make about the contents of
these scripts. Leadership is required across HCPs and patient groups to es-
tablish what best practice looks like for ULM scripts and support infrastruc-
ture such as training, information, digital traceability and guidance to
support their safe and effective use.
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